Astellas and Seagen (SGEN) Announce Presentation of Results from PADCEV Pivotal Trial in Patients with Previously Treated Advanced UC Who Were Ineligible for Cisplatin Chemotherapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
Go back to Astellas and Seagen (SGEN) Announce Presentation of Results from PADCEV Pivotal Trial in Patients with Previously Treated Advanced UC Who Were Ineligible for Cisplatin Chemotherapy
February 12, 2021 2:15 PM EST
TOKYO and BOTHELL, Wash., Feb. 12, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq: SGEN) today announced results from the second cohort (cohort 2) of patients in the pivotal phase 2 single-arm EV-201 trial. In the trial, 52 percent of patients who received PADCEV® (enfortumab vedotin-ejfv) had an objective response (95 percent Confidence Interval [CI]: 40.8, 62.4) and the median duration of response was 10.9 months (95 percent CI: 5.8, NR). Twenty percent of patients had a complete response, the absence of detectable cancer, after PADCEV treatment, and 31 percent had a... More